Methamphetamine-induced vascular changes lead to striatal hypoxia and dopamine reduction

Sharanya M Kousik1, Steven M Graves, T Celeste Napier

  • 1Department of Pharmacology and the Center for Compulsive Behaviors and Addiction, Rush University, Robert H. and Terri Cohn Research Building, 1735 West Harrison Street, Chicago, IL 60612, USA. sharanya_m_kousik@rush.edu

Neuroreport
|October 8, 2011
PubMed

Insights

Methamphetamine abuse may increase Parkinson's disease risk by damaging the blood-brain barrier and reducing blood flow to the brain, causing dopamine neuron loss. This neurotoxic mechanism involves hypoxia and striatal vasoconstriction.

Area of Science:

  • Neuroscience
  • Toxicology
  • Neurology

Background:

  • Methamphetamine (meth) is a psychostimulant linked to neurotoxicity.
  • Clinical observations suggest a correlation between meth abuse and an increased risk of Parkinson's disease.

Purpose of the Study:

  • To investigate the potential mechanisms by which methamphetamine abuse may increase the risk of Parkinson's disease.
  • To examine changes in the blood-brain barrier and cerebral vasculature following methamphetamine exposure in a rat model.

Main Methods:

  • Rats were administered methamphetamine acutely and trained to self-administer the drug.
  • Blood-brain barrier integrity was assessed.
  • Cerebral blood flow in the striatum was measured using imaging techniques.
  • Hypoxia and dopamine-related markers (tyrosine hydroxylase) in the striatum were evaluated.

Main Results:

  • Acute methamphetamine treatment led to observable blood-brain barrier leakage.
  • Both acute and chronic methamphetamine exposure resulted in hypoperfusion (reduced blood flow) in the striatum.
  • Striatal hypoperfusion was associated with hypoxia (oxygen deficiency).
  • Methamphetamine self-administration correlated with reduced levels of striatal tyrosine hydroxylase, a marker for dopamine neurons.

Conclusions:

  • Methamphetamine-induced neurotoxicity may involve damage to the blood-brain barrier and reduced cerebral blood flow.
  • Striatal vasoconstriction leading to hypoxia and subsequent dopamine neuron damage is a potential mechanism linking meth abuse to Parkinson's disease risk.
  • These findings highlight a novel pathway for methamphetamine's neurotoxic effects relevant to neurodegenerative disorders.

Related Concept Videos

Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids01:24

CNS Stimulants: Cocaine, Amphetamines and Cannabinoids

CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its effects by...
Stimulants01:29

Stimulants

Stimulants are substances that enhance neural activity and elevate dopamine levels in the brain, leading to their highly addictive nature. These drugs include cocaine, amphetamines, MDMA, caffeine, and nicotine, each with distinct mechanisms of action and varied health implications.
Cocaine can be administered via snorting, injection, or smoking. It primarily functions by blocking the reuptake of dopamine, resulting in a euphoric high characterized by an intense sensation of happiness and...
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
Attention-Deficit/Hyperactivity Disorder01:30

Attention-Deficit/Hyperactivity Disorder

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
Drug Abuse and Addiction: Pharmacological Phenomena01:15

Drug Abuse and Addiction: Pharmacological Phenomena

Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not necessarily...